Labs are a real bottleneck as they struggle to attract...

Labs are a real bottleneck as they struggle to attract backpackers and other manual workers who do the grunt work for sample prep.
Everyone is waiting longer than usual periods for assay results; it’s not management but longer that usual turnaround times from the Labs.
Bluebird will become a mine; the only question is how big?
Also because of the Options due date in April, there is no urgency to promote TMS and as most are held by the major shareholders ( and friends) they would know that the strike price is way under the real value so regardless of the SP they will convert, as you would not be able to buy the same quantity in the Market at anywhere near the strike price.
If the RES goes anywhere over 3MT ( it looks like it has the potential to double this) then TMS will have a money printing machine.
I would base my SP valuation on all the Options being converted and a RES of 4MT at a minimum.
Based on comparable assets, TMS has a long way to run before it hits parity with peer valuations.